Andreas Bulling is a Professor at the Institute for Visualisation and Interactive Systems , University of Stuttgart, Germany. His research focuses on Human-Computer Interaction , Eye Tracking , and Computer Vision , with applications in Machine Learning , Virtual Reality , and Information Visualization . 2025 Publications: HOIGaze (Extended Reality), ChartQC (Data Visualization), HAIFAI (Human-AI Interaction), SummAct (Behavioral Summarization), Chartist (Chart Reading). 2024 Contributions: HumanEYEze (Multimodal AI), HOIMotion (3D Object Detection), MultiMediate'24 (Engagement Estimation), Unified Model of Saliency (Scanpath Prediction). His recent work explores gaze estimation , interactive behavior modeling , and privacy-preserving eye-tracking systems . Key subfields include Extended Reality , Neural Networks , and Behavioral Biometrics . While no explicit scientific awards are mentioned, his research has been widely cited (8,003 total citations) and downloaded (132,740 times). Andreas leads projects in Interactive Systems and collaborates with institutions such as Aalto University , KU Leuven , and National University of Singapore . His lab focuses on eye movement analysis , human motion forecasting , and task-driven input modeling .
Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
Aisha Ameen is a Researcher in the Department of Veterinary and Animal Sciences (Pathobiological Sciences) at the University of Copenhagen's Faculty of Health and Medical Sciences, holding dual appointments as Research Assistant and Guest Researcher. Her research centers on Alzheimer's disease mechanisms with emphasis on astrocyte metabolism, glucose/glutamate dynamics, and short/medium-chain fatty acid roles. She employs functional metabolic mapping, dMRI, immunohistochemistry, and hiPSC models to investigate neurodegenerative processes at cellular and systemic levels. Analysis of her 2022-2025 publications reveals consistent focus on metabolic dysregulation in Alzheimer's pathology, particularly astrocyte energy substrate competition and fatty acid interventions. Her work bridges neuroscience, metabolism, and translational disease modeling with significant citation impact and media attention.
James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.
Un J. Kang, MD is the Founders Professor of Neurology at NYU Grossman School of Medicine and Professor in the Department of Neuroscience and Physiology. He serves as Director of Translational Research at the Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders and Co-Director of the Parekh Center for Interdisciplinary Neurology. His clinical practice focuses on Parkinson's disease and related movement disorders including tremor, dystonia, and Huntington's disease. Dr. Kang earned his MD from Johns Hopkins University in 1982, completed residency in Neurology at NY Presbyterian - Columbia University Medical Center in 1986, and specialized in Movement Disorders through fellowship training at the same institution in 1987. His research investigates the pathogenesis of Parkinson's disease and mechanisms of therapy, with particular focus on basal ganglia circuit plasticity, neural adaptation to dopamine loss, and development of biomarkers for neurodegenerative disorders. He pioneered experimental gene therapy approaches for Parkinson's disease and now directs the Kang Lab where his team studies how brain circuitry is perturbed by dopamine loss and pharmacological treatment in mouse models. Dr. Kang's research portfolio includes multiple NIH-funded projects examining striatal cholinergic interneuron dysfunction, freezing of gait mechanisms, and biomarker development for Parkinson's disease. His laboratory has published extensively on Parkinson's disease mechanisms with 178 publications to date, including significant recent work on alpha-synuclein detection methods and striatal pathway alterations in Parkinsonian motor deficits. Before joining NYU Langone in 2019, Dr. Kang created and led a multidisciplinary research team at the University of Chicago for two decades and previously served as chief of the movement disorders division at Columbia University. He leads the BioFIND consortium as principal investigator, banking biospecimens for Parkinson's disease biomarker discovery.
Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.
James Briscoe is a Senior Group Leader at The Francis Crick Institute in London, where he leads a research group focused on developmental biology and morphogen signaling. He previously held positions at the Medical Research Council's National Institute for Medical Research, which later became part of the Francis Crick Institute. Education: BSc in Microbiology and Virology from the University of Warwick, UK PhD from Imperial Cancer Research Fund/King's College London Postdoctoral training at Columbia University with Thomas Jessell Dr. Briscoe's research focuses on the molecular and cellular mechanisms of graded signaling by morphogens and the role of transcriptional networks in cell fate specification. His laboratory employs a range of experimental and computational techniques using model systems including mouse and chick embryos and embryonic stem cells. His work has significant implications for understanding developmental processes and their relationship to disease. His recent publications demonstrate a continued focus on morphogen gradients, neural tube development, and computational approaches to understanding cell fate decisions. His research increasingly integrates single-cell technologies and computational modeling to unravel the complexities of developmental patterning. Scientific Awards and Honors: EMBO Young Investigator (2001) EMBO Gold Medal (2008) Elected to EMBO (2009) Fellow of the Academy of Medical Sciences (2019) Fellow of the Royal Society (2019) As Editor-in-Chief of the journal Development since 2018, Dr. Briscoe plays a significant role in shaping the field of developmental biology. His leadership extends to mentoring researchers and contributing to scientific policy discussions, as evidenced by his recent publication 'Science under siege: protecting scientific progress in turbulent times.' Dr. Briscoe's laboratory at the Crick Institute is well-equipped with access to advanced facilities including light microscopy, flow cytometry, genomics, and computational resources, enabling a multidisciplinary approach to developmental biology questions.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Marie Sandberg is an Associate Professor in the Promotion Programme at the Saxo Institute, University of Copenhagen. She is affiliated with the Faculty of Humanities and participates in HUM:Global initiatives focused on interdisciplinary global studies. Her research emphasizes ethnological analyses of migration, borders, and refugee policies, particularly exploring temporal governance, state-civil society interactions, and the paradoxes of welfare-state frameworks. Her work examines the everyday practices of refugees and volunteers in contexts of temporary protection status, as well as the ethical challenges in digital migration studies. She contributes to debates on deterrence policies, repatriation agendas, and the precarity of academic labor. Sandberg’s research methodologies often combine ethnography with critical analysis of policy frameworks. Key Research Themes: Refugee temporariness, border studies, humanitarianism, and academic precarity Professional Roles: Member of the Professional Project Group (PPG) in HUM:Global, coordinating interdisciplinary projects Geographic Focus: Europe, with emphasis on Denmark, Poland, and Germany Recent publications highlight her focus on the interplay between state policies and grassroots efforts, as well as the temporal dimensions of displacement. She has co-edited special issues on migration and authored studies on volunteerism in refugee relief work.
Thibault Mayor is a Professor in the Department of Biochemistry and Molecular Biology and the Michael Smith Laboratories at the University of British Columbia (Vancouver). His research focuses on understanding how cells manage misfolded proteins, with implications for neurodegenerative diseases like Parkinson's and Alzheimer's. He holds academic affiliations with the Centre for High-Throughput Biology (CHiBi) and has been recognized with awards including the UBC Killam Teaching Award (2020). Education: BSc, University of Geneva, Switzerland (1997) PhD, University of Geneva & Max Planck Institute of Biochemistry, Germany (2001) Postdoctoral Fellow, California Institute of Technology (2002) Research Interests: Mayor's lab investigates protein homeostasis, ubiquitin-proteasome system dynamics, and the molecular mechanisms underlying protein aggregation in aging and disease. Projects include proteomic approaches to identify aggregation-prone proteins and develop microbial cell factories for protein production. Grants & Awards: CIHR Project Grant ($730K, 2018) Michael Smith Foundation Career Award (2012) UBC Killam Teaching Award (2020) Labs & Collaborations: The Mayor Lab is part of the Michael Smith Laboratories and collaborates with computational biologists like Jörg Gsponer. They maintain active partnerships in proteomics and systems biology, contributing to initiatives like the BC Proteomics Network.
Dr. Cassandra Sampaio Baptista is a Lecturer at the University of Glasgow's School of Psychology & Neuroscience. Her research focuses on brain plasticity in adulthood, particularly exploring how experiences like skill learning or rehabilitation influence structural and functional changes in the brain. She employs neuroimaging techniques such as fMRI neurofeedback and MRI to investigate mechanisms of myelin and white matter plasticity. Her work emphasizes translational applications, including stroke rehabilitation and promoting healthy aging. Key contributions include demonstrating myelin's role in motor learning and developing MRI protocols for white matter analysis. She collaborates on projects funded by the BIAL Foundation (2025–2026) and has supervised multiple postgraduate students. Recent publications highlight studies on oligodendrocyte dynamics, neurofeedback interventions for stroke survivors, and cross-species neuroscience approaches. While no specific awards are listed, her extensive publication record reflects her leadership in neuroplasticity research.
Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Marc V Fuccillo is an Associate Professor of Neuroscience at the Perelman School of Medicine, University of Pennsylvania, where he leads a research laboratory focused on understanding the neural circuit mechanisms underlying behavioral control. His work bridges molecular, synaptic, and behavioral approaches to investigate how striatal circuits regulate mouse behavior from simple motor patterns to complex goal-directed actions. Fuccillo holds dual appointments in the Neuroscience and Cell and Molecular Biology Graduate Groups at Penn and maintains an active laboratory investigating the synaptic and circuit basis of neuropsychiatric disorders. Education: B.A. in Molecular and Cellular Biology and Music Performance (Violin) from Brown University (1998) Ph.D. in Developmental Genetics from New York University School of Medicine (2007) M.D. from New York University School of Medicine (2008) Fuccillo's research centers on the synaptic and circuit mechanisms of behavioral control, with particular emphasis on striatal circuits. His laboratory employs a range of technologies including mouse genetics, in vitro electrophysiology, in vivo imaging, and quantitative behavioral analysis to explore how neural circuits of the striatum regulate behavior and how disruptions in these circuits contribute to neuropsychiatric disorders. His work has particularly focused on autism-associated abnormalities in behavioral control, examining how synaptic adhesion molecules like neuroligins and neurexins shape circuit function and behavior, with significant findings regarding D1 dopamine receptor positive medium spiny neurons in the nucleus accumbens. Analysis of Fuccillo's recent publications reveals a strong focus on striatal circuit function across multiple dimensions. His work spans molecular neuroscience (examining synaptic adhesion molecules), cellular physiology (studying specific neuron types in striatal circuits), systems neuroscience (mapping circuit connectivity), and behavioral neuroscience (quantifying motor learning and decision-making). A unifying theme is how disruptions in specific molecular pathways lead to circuit-level abnormalities that manifest as behavioral phenotypes relevant to neuropsychiatric disorders, with particular attention to autism, OCD, and schizophrenia models. Scientific Recognition: Publications in high-impact journals including Nature Neuroscience, Current Biology, Cell Reports, and Neuron Research supported by multiple NIH grants including NIMH F32, NIMH K01, and HHMI Gilliam Fellowship awards for lab members Fuccillo actively mentors a diverse group of trainees including postdoctoral fellows, graduate students, and undergraduates. His laboratory has produced numerous successful alumni who have gone on to faculty positions, medical residencies, and graduate programs at prestigious institutions. His mentoring approach emphasizes technical skill development across multiple neuroscience disciplines while fostering independent scientific thinking. Current research in his lab is supported by NIH funding focused on understanding the molecular architecture of striatal circuits and their role in behavioral control, with three major research directions exploring molecular logic of striatal circuits, circuit mechanisms of behavioral control, and striatal dysfunction in neuropsychiatric disease models. The Fuccillo Laboratory operates within the Department of Neuroscience at the University of Pennsylvania, with access to state-of-the-art facilities for molecular, electrophysiological, imaging, and behavioral neuroscience research. The lab maintains active collaborations with other neuroscience research groups at Penn and beyond, creating a rich intellectual environment for studying the neural basis of behavior. Current research directions include investigating whether there is a molecular logic to striatal circuit composition, how striatal circuits shape behavioral control, and what mouse models of autism, schizophrenia, and OCD can reveal about striatal circuit dysfunction in disease pathophysiology.
University of California, Los AngelesUnited States
David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.
